U.S. Metals and Mining Stock News

In early May 2026, Life Time Group Holdings reported first-quarter results showing year-on-year increases in sales to US$767.57 million, total revenue to US$788.7 million, and net income to US$88.1 million, alongside higher earnings per share. The company also raised its full-year 2026 revenue and net income guidance, while continuing to open large-format clubs and repurchasing shares, underscoring how earnings growth, expansion, and capital allocation are moving together. We’ll now examine...

Quaker Chemical Corporation recently reported past first-quarter 2026 results, with sales of US$480.48 million and net income of US$19.67 million, both higher than a year earlier. The jump in basic and diluted earnings per share from continuing operations to US$1.13 suggests improving efficiency and stronger profitability across the business. With earnings per share improving materially year over year, we’ll now examine how this update reshapes Quaker Chemical’s investment narrative. Invest...

In recent months, RBC Bearings has been highlighted in multiple fund investor letters for past strong quarterly results supported by aerospace and defense demand, price increases, content gains, and improving aircraft production rates, alongside a record backlog that signals resilient order momentum. These fund commentaries, combined with expectations for year-over-year earnings and revenue growth in the March 2026 quarter, have reinforced investor focus on RBC Bearings’ record order book as...

Summit Therapeutics Inc. has already reported first-quarter 2026 results, with net loss widening to US$189.42 million and basic and diluted loss per share from continuing operations at US$0.24, compared with US$62.91 million and US$0.09 a year earlier. This sharp increase in quarterly losses may prompt investors to reassess how Summit’s spending and cash use align with its late-stage oncology pipeline. Next, we’ll examine how this much larger quarterly net loss shapes Summit’s existing...

Wondering whether NCR Voyix at US$8.09 is starting to look cheap, or still carries too much risk for the price you pay? The stock has moved sharply in the short term, with a 17.4% return over 7 days and 29.2% over 30 days, although returns are negative at 18.0% year to date and 20.4% over 1 year. These recent moves sit against a longer track record that includes 42.7% and 71.8% returns over 3 and 5 years respectively. These figures may reflect shifting sentiment and changing expectations for...

Zimmer Biomet Holdings reported past first-quarter 2026 results with sales of US$2,086.7 million and net income of US$238.1 million, reaffirming its full-year revenue guidance. Alongside continued share repurchases, the company announced the departure of its CFO and appointed its Controller and Chief Accounting Officer as interim CFO, raising questions about leadership continuity in its finance function. Next, we’ll examine how reaffirmed guidance alongside the CFO transition may influence...

Apple’s recent performance and scale Apple (AAPL) is drawing investor attention as its stock recently closed at $293.32, with returns of 2% over the past day, 4.7% over the past week, and 12.6% over the past month. Over the past 3 months, the stock shows a 6.8% return, while the 1 year total return stands at 48.4%. Longer term, Apple’s 3 year and 5 year total returns are 72.2% and 135.9% respectively, illustrating sizeable compounding over time. The company operates at a large scale,...

Shift4 Payments (FOUR) is back in focus after its first quarter 2026 earnings, reporting revenue of US$1.12b and net income of US$15 million, along with new high profile sports venue partnerships. See our latest analysis for Shift4 Payments. The stock reacted sharply to the Q1 2026 update, with a 1-day share price return of 9.26% and a 30-day share price return of 16.34%. However, the year-to-date share price return of 25.26% and 1-year total shareholder return of 45.16% both remain weak,...

If you are wondering whether Altria Group stock still offers value at around US$69.04, it helps to start by lining up its price against what the fundamentals suggest. The stock has seen a 5.0% decline over the last 7 days, while returns sit at 4.2% over 30 days, 20.5% year to date and 22.3% over 1 year, with very large gains over 3 and 5 years of 91.1% and 103.3% respectively, which can change how you think about both opportunity and risk. Recent coverage has focused on Altria Group's...

ICON stock performance snapshot after recent moves ICON (ICLR) has caught investor attention after a recent share price move, with the stock closing at $125. Short term returns show mixed momentum, including a 0.7% gain over the past day. Over the past week and month, ICON has recorded returns of 5.6% and 16.6% respectively. Performance over the past 3 months and year to date reflects double digit declines, highlighting uneven sentiment around the stock. See our latest analysis for ICON. That...

In early May 2026, Innoviva, Inc. reported first-quarter 2026 results, with revenue of US$97.99 million and net income of US$186.6 million, marking a clear turnaround from the prior year’s loss. Around the same time, Innoviva filed a US$207.99 million shelf registration for up to 9,000,000 common shares tied to its employee stock ownership plan, underscoring management’s focus on employee alignment alongside growth in its recurring royalty and Specialty Therapeutics businesses. We’ll now...

Why IDEX (IEX) is back on investors’ radar IDEX (IEX) has drawn fresh attention after reporting first quarter 2026 results with higher sales and net income, declaring its 126th consecutive quarterly dividend and updating investors on completed share repurchases. See our latest analysis for IDEX. The earnings beat, long dividend record and fresh buyback activity come after a strong run, with a 30 day share price return of 12.01% and a 1 year total shareholder return of 18.18%, suggesting...

Why Catalyst Pharmaceuticals Stock Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has drawn attention after a period of strong share-price moves, with returns over the past month, past 3 months and year all in positive territory according to recent performance data. For investors tracking US biopharmaceutical stocks focused on rare diseases, this kind of sustained positive return profile can prompt a closer look at how the current share price relates to earnings, profitability and...

SoFi Technologies (SOFI) has drawn fresh attention after reporting Q1 2026 earnings that included US$1.1b in net revenue, net income of US$166.7 million, and record loan and deposit balances. See our latest analysis for SoFi Technologies. Despite strong Q1 results, SoFi’s recent 1-day and 90-day share price returns of 1.84% and 23.3% declines contrast with a 1-year total shareholder return of 20.66% and a 3-year total shareholder return above 3x. This points to fading near term momentum but...

Why Hawkins (HWKN) Is On Investors’ Radar Recent trading in Hawkins (HWKN) has drawn attention after the stock’s recent month and past 3 months performance, prompting investors to reassess what the current price of $167.01 implies. With returns of 13.88% over the past month and 24.28% in the past 3 months, Hawkins’ recent move sits against a backdrop of longer term total returns and a business spanning water treatment, industrial chemicals, and health and nutrition ingredients. See our latest...

Aurinia Pharmaceuticals (AUPH) has drawn fresh attention after reporting first quarter 2026 results. Revenue was US$77.71 million and net income was US$34.36 million, both higher than the prior year period. See our latest analysis for Aurinia Pharmaceuticals. The earnings beat and reiterated 2026 guidance arrived alongside a 4.9% 90 day share price return and an 86.7% 1 year total shareholder return, suggesting strong recent momentum despite short term share price weakness. If Aurinia’s...

Earnings and dividend announcement set the tone for Crown Holdings stock Crown Holdings (CCK) recently reported first quarter 2026 results alongside an affirmation of its regular quarterly dividend, giving investors fresh information on both the company’s operating performance and its ongoing cash return policy. See our latest analysis for Crown Holdings. The recent earnings release, which showed quarterly sales of US$3,259 million and net income of US$175 million, together with the affirmed...

Cimpress plc has reported past third-quarter 2026 results showing sales of US$886.21 million versus US$789.47 million a year earlier, with net income of US$13.84 million compared with a net loss of US$8.24 million and basic earnings per share from continuing operations improving from US$0.33 loss to US$0.57. Over the first nine months to March 31, 2026, Cimpress lifted sales to US$2.79 billion and more than doubled net income to US$70.82 million, highlighting materially stronger...

Walker & Dunlop, Inc. has reported past first-quarter 2026 results, with revenue rising to US$301.33 million and net income to US$15.87 million, alongside affirming a quarterly dividend of US$0.68 per share payable on June 4, 2026. Beneath these headline figures, the company highlighted very large growth in transaction volumes and agency lending, supported by complex refinancing deals and higher productivity per banker that helped increase its share of the GSE lending market. We’ll now...

What recent returns say about MakeMyTrip stock MakeMyTrip (MMYT) has moved sharply in recent months, with a 2.1% gain over the past day, about 7% over the past week, and roughly 32% over the past month. See our latest analysis for MakeMyTrip. While the recent 32% 1 month share price return points to strong short term momentum, this comes after a 38.3% year to date share price decline and a 48% 1 year total shareholder return loss, set against much stronger 3 and 5 year total shareholder...

Armstrong World Industries (AWI) has put investors on alert after its first quarter 2026 update, combining higher year-on-year sales, slightly lower net income and a reaffirmed full year net sales outlook. See our latest analysis for Armstrong World Industries. The reaffirmed 2026 net sales outlook and management's focus on M&A have come after a 16.7% decline in the 90 day share price return, even as the 3 year total shareholder return sits at 157.8%. This suggests long term momentum has been...

Jacobs Solutions (NYSE:J) has been selected as part of a joint venture to design five new underground stations for Sydney Metro West. The contract covers integrated engineering design services for Australia’s largest transportation project. The win expands Jacobs Solutions’ global transportation infrastructure footprint, with a focus on high-performance, sustainable mass transit. For investors watching the infrastructure and engineering space, this new Sydney Metro West mandate puts Jacobs...

Pebblebrook Hotel Trust stock moves draw investor focus Pebblebrook Hotel Trust (PEB) is back on many investors’ radars after a recent stretch of positive share price performance, with the stock up over the past month and past 3 months. See our latest analysis for Pebblebrook Hotel Trust. That recent upswing fits into a broader recovery story, with a 30 day share price return of 13.88% and a 1 year total shareholder return of 53.71% pointing to improving momentum despite a weak 5 year total...

Why Chemours stock is on investors’ radar Chemours (CC) has drawn fresh attention after its first quarter 2026 earnings, where several business segments outperformed expectations, and management highlighted debt reduction, refinancing activity, and reaffirmed full year sales and EBITDA guidance. See our latest analysis for Chemours. That interest has come against a sharp pullback in recent days, with a 1 day share price return of 5.32% decline and a 7 day share price return of 16.85% decline,...